Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 317 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Happy Nurses Month! May 3, 2021 FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour April 4, 2025 Combination of Immunotherapy Drugs Approved for Metastatic Colorectal Cancer August 3, 2018 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 Load more HOT NEWS Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... Withdrawal of the Application to Change the EMA Marketing Authorisation for... Efficacy of Rituximab Maintenance in Patients with Mantle Cell Lymphoma Who... EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan
